You searched for "Prostate cancer"
Prostate Cancer UK: Towards Equity: Exploring Prostate Cancer Disparities Experienced by Black Men - data and evidence mini conference (Free)
We will delve into why Prostate Cancer UK is exploring health inequalities, starting with Black men and highlight valuable research findings and challenges in health inequalities space, with keynote speaker Dr Tom Cowling, who will share his insights from the latest England and Wales NPCA State of the Nation Report, including sociodemographic and tumour data from England. From 1.30 pm - 4.30pmProstate Cancer UK: Faster Diagnosis Standard: Short course (20 weeks long) Deadline 5 Jan 2025 (Free)
You will learn some best practice models and drive change in your Trust, constructing a model with industry experts to deliver a new pathway that works for your patients. Unlock the potential to implement Faster Diagnosis Standards and accelerate diagnosis for men affected by prostate cancer with our free 20-week leadership programme. Guided by expert programme managers, you'll shape and implement your own project and gain crucial leadership and change management skills. We’ll support you from the initial planning stages of your project through to implementation and review.Prostate Cancer UK: Clinical Champions: Flagship long course (18 months) Deadline 2 Feb 2025 (Free)
Our award-winning long course, the Clinical Champions is all about driving change in your trust and broadening your professional soft-skill set. Our programme will support and inspire you to drive meaningful improvements for people living with or at risk of prostate cancer. To apply, you’ll need an improvement project and to demonstrate how you’d like to expand your leadership skills. As part of the programme you will receive: - Training on change leadership, system leadership, improvement science and implementing an improvement project. - Virtual improvement group meetings that allow time to connect with peers. - Individual support around your improvement ambitions and leadership development. - Opportunities to meet and network with inspiring leaders.BXTAccelyon becomes global distribution partner for new online prostate MRI self-learning tool to enhance prostate cancer diagnosis
BXTAccelyon, the leading low dose rate (LDR) brachytherapy partner to hospitals and clinics worldwide, and distribution partner for PrecisionPoint™, the...New ultrasound imaging technique reliably spots prostate cancer, initial patient trial reveals
A groundbreaking new imaging approach developed by researchers at Heriot-Watt University has shown ‘extremely encouraging’ results in early-stage clinical trials on prostate cancer at the Western General Hospital in Edinburgh, Scotland. The ongoing clinical trial demonstrated an initial 94% sensitivity...NHS Greater Glasgow and Clyde Prostate Cancer Nurse Specialist wins Continence and Urology Nurse of the Year at BJN Awards 2025
Leann McLaughlin, a Uro-Oncology CNS who specialises in prostate cancer at Inverclyde Royal Hospital, NHS Greater Glasgow and Clyde, has won Urology and Continence Nurse of the Year at the British Journal of Nursing (BJN) Awards 2025. The prestigious event...Prostate Scotland’s COMPASS Impact Report highlights how men in Scotland are benefiting from prostate cancer support services
Prostate Scotland has published its COMPASS Impact Report 2020-2024, providing a detailed account of how its support services are improving outcomes for men living with prostate cancer across Scotland. Developed to complement care provided by clinical teams, COMPASS helps men...Catheters and incontinence after radical prostatectomy: Preparing (but not scaring) men
Every year about 6000 men in the UK undergo radical prostatectomy (RP) for treatment of prostate cancer [1]. Despite surgical advances, RP continues to be associated with significant side-effects including urinary incontinence (UI) [2]. Immediately following removal of the urinary...Consensus statements on PSA testing in asymptomatic men in the UK
In January 2016, the UK National Screening Committee once again recommended against a systematic population screening programme for prostate cancer due to the, as yet, insufficient evidence that the benefits of screening would outweigh the harm to the population as...
